{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T19:19:53Z","timestamp":1770923993496,"version":"3.50.1"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Natural Science Foundation of Shandong Province","award":["ZR2023QH053"],"award-info":[{"award-number":["ZR2023QH053"]}]},{"name":"Jinan Clinical Medical Technology Innovation Plan","award":["202328047"],"award-info":[{"award-number":["202328047"]}]},{"name":"Cultivation Fund of the Second Hospital of Shandong University","award":["2022YP84"],"award-info":[{"award-number":["2022YP84"]}]},{"name":"Cultivation Fund of the Second Hospital of Shandong University","award":["2022YP100"],"award-info":[{"award-number":["2022YP100"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    In contrast to cancers with high immunotherapy responsiveness, such as lung cancer and melanoma, thyroid carcinoma (THCA) immunotherapy remains investigational. To establish a theoretical foundation for THCA immunotherapy, we investigated the association between genetic mutations and tumor microenvironment (TME) by analyzing RNA-sequencing data and somatic mutation profiles from 571 THCA samples in The Cancer Genome Atlas (TCGA) database. The ESTIMATE algorithm was first applied to calculate ImmuneScores and StromalScores. Samples were subsequently stratified into immune-high and immune-low groups, as well as stromal-high and stromal-low groups, based on median score thresholds. We then identified differentially expressed genes (DEGs) and differentially mutated genes (DMGs). Significant disparities in mutation frequencies of\n                    <jats:italic>BRAF<\/jats:italic>\n                    ,\n                    <jats:italic>NRAS<\/jats:italic>\n                    , and\n                    <jats:italic>HRAS<\/jats:italic>\n                    were observed both between immune stratification groups (high vs low) and stromal stratification groups (high vs low). Correlation analysis between DMGs and clinicopathological features revealed that\n                    <jats:italic>BRAF<\/jats:italic>\n                    \/\n                    <jats:italic>NRAS<\/jats:italic>\n                    expression levels were associated with THCA clinical stage. CIBERSORT computational algorithm was also used to quantify the relative abundance of tumor-infiltrating immune cells (TICs), demonstrating that 11 types of activated TICs were strongly associated with\n                    <jats:italic>BRAF<\/jats:italic>\n                    expression. Finally, we examined target DMGs expression in relation to immune checkpoint proteins (ICPs) to identify potential therapeutic targets. THCA specimens with suppressed\n                    <jats:italic>BRAF<\/jats:italic>\n                    expression demonstrated upregulated ICPs expression, indicating potential susceptibility to checkpoint blockade immunotherapy.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0341123","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:30:58Z","timestamp":1770921058000},"page":"e0341123","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of the tumor microenvironment on genetic mutations in thyroid carcinoma"],"prefix":"10.1371","volume":"21","author":[{"given":"Lingyan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwen","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5488-2139","authenticated-orcid":true,"given":"Shihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"3","key":"pone.0341123.ref001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"pone.0341123.ref002","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4158\/EP-2018-0130","article-title":"Implementing Key Changes in the American Thyroid Association 2015 Thyroid Nodules\/Differentiated Thyroid Cancer Guidelines Across Practice Types","volume":"24","author":"CL Twining","year":"2018","journal-title":"Endocr Pract"},{"issue":"1","key":"pone.0341123.ref003","first-page":"1","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"R Zheng","year":"2022","journal-title":"J Natl Cancer Cent"},{"issue":"5","key":"pone.0341123.ref004","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3803\/EnM.2022.1553","article-title":"Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach","volume":"37","author":"CK Jung","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"12","key":"pone.0341123.ref005","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","article-title":"A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995","volume":"83","author":"SA Hundahl","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"pone.0341123.ref006","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00268-018-4479-z","article-title":"Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients","volume":"42","author":"Y Ito","year":"2018","journal-title":"World J Surg"},{"issue":"5","key":"pone.0341123.ref007","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/thy.1999.9.421","article-title":"An overview of the management of papillary and follicular thyroid carcinoma","volume":"9","author":"EL Mazzaferri","year":"1999","journal-title":"Thyroid"},{"issue":"6","key":"pone.0341123.ref008","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.surg.2013.07.008","article-title":"A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up","volume":"154","author":"RH Grogan","year":"2013","journal-title":"Surgery"},{"issue":"3","key":"pone.0341123.ref009","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","article-title":"Current practice in patients with differentiated thyroid cancer","volume":"17","author":"M Schlumberger","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"pone.0341123.ref010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12020-023-03415-6","article-title":"Potential impacts of SARS-CoV-2 on parathyroid: current advances and trends","volume":"81","author":"AK Murugan","year":"2023","journal-title":"Endocrine"},{"issue":"1","key":"pone.0341123.ref011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12943-018-0786-0","article-title":"Novel targeted therapies and immunotherapy for advanced thyroid cancers","volume":"17","author":"GE Naoum","year":"2018","journal-title":"Mol Cancer"},{"issue":"3","key":"pone.0341123.ref012","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cells11030320","article-title":"Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects","volume":"11","author":"S Tang","year":"2022","journal-title":"Cells"},{"issue":"10304","key":"pone.0341123.ref013","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"MS Carlino","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"pone.0341123.ref014","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/imt-2023-0174","article-title":"Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives","volume":"16","author":"A Daste","year":"2024","journal-title":"Immunotherapy"},{"key":"pone.0341123.ref015","doi-asserted-by":"crossref","first-page":"1643421","DOI":"10.3389\/fimmu.2025.1643421","article-title":"Advances in PD-1\/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives","volume":"16","author":"X Li","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0341123.ref016","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12967-016-0958-x","article-title":"Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer","volume":"14","author":"AK Murugan","year":"2016","journal-title":"J Transl Med"},{"key":"pone.0341123.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.10.022","article-title":"Special issue: PI3K\/Akt signaling in human cancer","volume":"59","author":"AK Murugan","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"pone.0341123.ref018","doi-asserted-by":"crossref","first-page":"1076640","DOI":"10.3389\/fendo.2023.1076640","article-title":"STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma","volume":"14","author":"W He","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"pone.0341123.ref019","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"CC Smith","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"pone.0341123.ref020","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"S Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6561","key":"pone.0341123.ref021","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1126\/science.abg5784","article-title":"The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation","volume":"373","author":"TD Martin","year":"2021","journal-title":"Science"},{"issue":"6559","key":"pone.0341123.ref022","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1048","article-title":"Developmental chromatin programs determine oncogenic competence in melanoma","volume":"373","author":"A Baggiolini","year":"2021","journal-title":"Science"},{"key":"pone.0341123.ref023","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"K Yoshihara","year":"2013","journal-title":"Nat Commun"},{"issue":"11","key":"pone.0341123.ref024","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"A Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"pone.0341123.ref025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fendo.2020.00102","article-title":"Update on Fundamental Mechanisms of Thyroid Cancer","volume":"11","author":"A Prete","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"19","key":"pone.0341123.ref026","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2174\/1871520623666230607125258","article-title":"In silico Screening and Validation of Achyranthes aspera as a Potential Inhibitor of BRAF and NRAS in Controlling Thyroid Cancer","volume":"23","author":"AM Alamri","year":"2023","journal-title":"Anticancer Agents Med Chem"},{"key":"pone.0341123.ref027","doi-asserted-by":"crossref","first-page":"961450","DOI":"10.3389\/fmolb.2022.961450","article-title":"Identification of immune-related ferroptosis prognostic marker and in-depth bioinformatics exploration of multi-omics mechanisms in thyroid cancer","volume":"9","author":"X Fan","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"7","key":"pone.0341123.ref028","article-title":"TTN mutations predict a poor prognosis in patients with thyroid cancer","volume":"42","author":"X Han","year":"2022","journal-title":"Biosci Rep"},{"issue":"4","key":"pone.0341123.ref029","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/lary.23838","article-title":"Diagnosis and management of differentiated thyroid cancer using molecular biology","volume":"123","author":"RL Witt","year":"2013","journal-title":"Laryngoscope"},{"issue":"2","key":"pone.0341123.ref030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/path.5005","article-title":"Genetic landscape of papillary thyroid carcinoma in the Chinese population","volume":"244","author":"J Liang","year":"2018","journal-title":"J Pathol"},{"issue":"8","key":"pone.0341123.ref031","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2362.2009.02162.x","article-title":"Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination","volume":"39","author":"S Guth","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"pone.0341123.ref032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO Classification of Thyroid Neoplasms","volume":"33","author":"ZW Baloch","year":"2022","journal-title":"Endocr Pathol"},{"issue":"1","key":"pone.0341123.ref033","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","article-title":"Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer","volume":"64","author":"S Cantara","year":"2019","journal-title":"Endocrine"},{"key":"pone.0341123.ref034","doi-asserted-by":"crossref","first-page":"1476030","DOI":"10.3389\/fimmu.2024.1476030","article-title":"NF-\u03baB signaling pathway in tumor microenvironment","volume":"15","author":"Y Cao","year":"2024","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0341123.ref035","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1600-6143.2006.01372.x","article-title":"T regulatory cells and migration","volume":"6","author":"D Chen","year":"2006","journal-title":"Am J Transplant"},{"issue":"7","key":"pone.0341123.ref036","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"F Balkwill","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"pone.0341123.ref037","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2174\/138920111798376987","article-title":"Tumor immune escape mechanisms that operate during metastasis","volume":"12","author":"DO Croci","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"issue":"4","key":"pone.0341123.ref038","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a037424","article-title":"The Immune Microenvironment and Cancer Metastasis","volume":"10","author":"A El-Kenawi","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"pone.0341123.ref039","doi-asserted-by":"crossref","first-page":"676731","DOI":"10.1155\/2012\/676731","article-title":"Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins","volume":"2012","author":"G Bendas","year":"2012","journal-title":"Int J Cell Biol"},{"issue":"1","key":"pone.0341123.ref040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00262-014-1619-7","article-title":"Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2\/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy","volume":"64","author":"SZ Simonovic","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"pone.0341123.ref041","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Y Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"pone.0341123.ref042","doi-asserted-by":"crossref","first-page":"9959649","DOI":"10.1155\/2022\/9959649","article-title":"Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma","volume":"2022","author":"X Wei","year":"2022","journal-title":"Biomed Res Int"},{"issue":"12","key":"pone.0341123.ref043","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.21037\/gs-22-701","article-title":"Combined expression of the BRAFV600E mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence-a retrospective cohort study","volume":"11","author":"M Zhang","year":"2022","journal-title":"Gland Surg"},{"issue":"9","key":"pone.0341123.ref044","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/ijc.32041","article-title":"Anti-PD-1\/PD-L1 therapy augments lenvatinib\u2019s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer","volume":"144","author":"V Gunda","year":"2019","journal-title":"Int J Cancer"},{"issue":"12","key":"pone.0341123.ref045","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.12998\/wjcc.v10.i12.3849","article-title":"Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report","volume":"10","author":"D-X Ma","year":"2022","journal-title":"World J Clin Cases"},{"issue":"1","key":"pone.0341123.ref046","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00384-018-3202-8","article-title":"Current status of immunotherapy in metastatic colorectal cancer","volume":"34","author":"P Wrobel","year":"2019","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"pone.0341123.ref047","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"DM Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"pone.0341123.ref048","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"L Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"pone.0341123.ref049","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Y Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"6127","key":"pone.0341123.ref050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"JF Brunet","year":"1987","journal-title":"Nature"},{"issue":"7","key":"pone.0341123.ref051","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer","volume":"101","author":"JJ Bastman","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:31:05Z","timestamp":1770921065000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341123"}},"subtitle":[],"editor":[{"given":"Avaniyapuram Kannan","family":"Murugan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341123","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}